Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLSD
Previous Symbol
CUSIPN/A
Phone678-270-3631
Debt
Debt-to-Equity Ratio0.22
Current Ratio4.59
Quick Ratio4.59
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$340,000.00
Price / Sales165.75
Cash FlowN/A
Price / CashN/A
Book Value$0.84 per share
Price / Book2.10
Profitability
EPS (Most Recent Fiscal Year)($2.33)
Net Income$-58,970,000.00
Net MarginsN/A
Return on Equity-142.46%
Return on Assets-102.76%
Miscellaneous
Employees34
Outstanding Shares32,020,000
Market Cap$51.88 million
OptionableOptionable
Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions
What is Clearside Biomedical's stock symbol?
Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."
How were Clearside Biomedical's earnings last quarter?
Clearside Biomedical Inc (NASDAQ:CLSD) issued its quarterly earnings results on Thursday, November, 8th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.12. View Clearside Biomedical's Earnings History.
When is Clearside Biomedical's next earnings date?
What price target have analysts set for CLSD?
8 brokers have issued 1-year price targets for Clearside Biomedical's shares. Their forecasts range from $4.00 to $29.00. On average, they anticipate Clearside Biomedical's share price to reach $12.7143 in the next twelve months. This suggests a possible upside of 622.4% from the stock's current price. View Analyst Price Targets for Clearside Biomedical.
What is the consensus analysts' recommendation for Clearside Biomedical?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clearside Biomedical.
Has Clearside Biomedical been receiving favorable news coverage?
Media coverage about CLSD stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Clearside Biomedical earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Clearside Biomedical's key competitors?
Some companies that are related to Clearside Biomedical include OASMIA PHARMACE/ADR (OASM), Corvus Pharmaceuticals (CRVS), Aeglea Bio Therapeutics (AGLE), Calithera Biosciences (CALA), Newron Pharmaceuticals (NWPHF), Intec Pharma (NTEC), Spring Bank Pharmaceuticals (SBPH), Bellicum Pharmaceuticals (BLCM), Ardelyx (ARDX), AcelRx Pharmaceuticals (ACRX), Marinus Pharmaceuticals (MRNS), Poxel (PXXLF), Nature's Sunshine Products (NATR), Molecular Templates (MTEM) and Chimerix (CMRX).
Who are Clearside Biomedical's key executives?
Clearside Biomedical's management team includes the folowing people:
- Mr. Daniel H. White, Founder, Pres, CEO & Director (Age 51)
- Mr. Charles A. Deignan, CFO & Sec. (Age 54)
- Dr. Glenn Noronha, Chief Scientific Officer (Age 53)
- Mr. Leslie B. Zacks, Gen. Counsel & Chief Compliance Officer (Age 49)
- Mr. Brion S. Raymond, Chief Commercial Officer (Age 48)
When did Clearside Biomedical IPO?
(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.
Who are Clearside Biomedical's major shareholders?
Clearside Biomedical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.94%), Sphera Funds Management LTD. (3.61%), AWM Investment Company Inc. (2.73%), Northpointe Capital LLC (2.15%), Sofinnova Ventures Inc (1.90%) and JPMorgan Chase & Co. (0.90%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Christy L Shaffer, Clay Thorp, Daniel H White, Gerald D Cagle and Venture Advisors Iii Hatteras. View Institutional Ownership Trends for Clearside Biomedical.
Which institutional investors are selling Clearside Biomedical stock?
Which institutional investors are buying Clearside Biomedical stock?
CLSD stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., AWM Investment Company Inc., Nexthera Capital LP, Sofinnova Ventures Inc, Dimensional Fund Advisors LP, Sphera Funds Management LTD. and Russell Investments Group Ltd.. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Christy L Shaffer, Daniel H White and Gerald D Cagle. View Insider Buying and Selling for Clearside Biomedical.
How do I buy shares of Clearside Biomedical?
Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clearside Biomedical's stock price today?
One share of CLSD stock can currently be purchased for approximately $1.76.
How big of a company is Clearside Biomedical?
Clearside Biomedical has a market capitalization of $51.88 million and generates $340,000.00 in revenue each year. The company earns $-58,970,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Clearside Biomedical employs 34 workers across the globe.
What is Clearside Biomedical's official website?
How can I contact Clearside Biomedical?
Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]
MarketBeat Community Rating for Clearside Biomedical (NASDAQ CLSD)
MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote "Outperform" if you believe CLSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days.
